DMD and Duchenne muscular dystrophy: A recent study reported that five DMD patients from 4 different clinical trials by Sarepta, Roche (using Sarepta’s vector), Pfizer, and Genethon receiving three different gene therapy products differing in AAV serotype, promoter, and dose, showed strikingly similar severe adverse advents that suggested a cytotoxic T-cell immune response against micro-dystrophin proteins52.